How Investors May Respond To DENTSPLY SIRONA (XRAY) Revenue Contraction And Persistently Negative Returns

• DENTSPLY SIRONA recently reported softer quarterly results, with average constant-currency revenue falling 5.5% year-on-year over the past two years and return on invested capital remaining negative.
• This combination of shrinking revenues and declining returns on invested capital highlights operational challenges that may be linked to intensifying competition or market saturation in key categories.
• We’ll now examine how DENTSPLY SIRONA’s continued revenue declines and weakening returns could influence its existing investment narrative and risk profile.

Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

DENTSPLY SIRONA Investment Narrative Recap

To own DENTSPLY SIRONA today, you need to believe it can turn ongoing revenue declines and negative returns on invested capital into a more efficient, profitable dental platform. The latest softer results reinforce that the most important near term catalyst is credible operational improvement, while the biggest current risk is that shrinking sales and weak ROIC signal deeper demand or competitive issues. The recent news appears material to both, as it questions how quickly any turnaround can take hold.

Against this backdrop, the February 2026 guidance calling for 2026 net sales of US$3.5 billion to US$3.6 billion stands out. That outlook sits alongside continued losses and follows full year 2025 sales of US$3.68 billion, framing how management sees the near term revenue base while investors weigh the impact of competition, tariffs and softness in elective categories on margins and eventual profitability.

Yet in contrast, investors should be aware of how sustained revenue pressure could interact with rising tariffs and weak elective procedure demand...

Read the full narrative on DENTSPLY SIRONA (it's free!)

DENTSPLY SIRONA's narrative projects $3.7 billion revenue and $161.6 million earnings by 2029.

Uncover how DENTSPLY SIRONA's forecasts yield a $14.54 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Before this setback, the most pessimistic analysts already assumed revenue would shrink about 0.8 percent a year to roughly US$3.8 billion by 2028, so this fresh weakness may prompt you to reconsider whether their more cautious view on competitive risks now looks closer to the mark or still too harsh.

Explore 4 other fair value estimates on DENTSPLY SIRONA - why the stock might be worth just $14.54!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your DENTSPLY SIRONA research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free DENTSPLY SIRONA research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DENTSPLY SIRONA's overall financial health at a glance.

Interested In Other Possibilities?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com